tetano
Editor, Senior Moderator
Eur J Clin Invest
. 2021 Apr 18;e13573.
doi: 10.1111/eci.13573. Online ahead of print.
SARS-CoV-2 antibodies: comparison of three high-throughput immunoassays versus the neutralization test
Riccardo Laterza[SUP] 1 [/SUP], Annalisa Schirinzi[SUP] 1 [/SUP], Rossella Bruno[SUP] 2 [/SUP], Rosa Genco[SUP] 1 [/SUP], Renato Contino[SUP] 1 [/SUP], Angelo Ostuni[SUP] 2 [/SUP], Francesca Di Serio[SUP] 1 [/SUP]
Affiliations
Abstract
On March 11, 2020 the World Health Organization (WHO) declared the novel coronavirus (SARS-CoV-2) outbreak a global pandemic.[SUP]1[/SUP] Currently, no specific therapy has proved to be effective against the infection. With the approval by WHO[SUP]2[/SUP] of the first vaccine for emergency use against SARS-CoV-2 on December 31, 2020, it is important to understand the strength and duration of immunity after administration, which is induced by neutralizing anti-SARS-CoV-2 S antibodies (nAbs).[SUP]3[/SUP] The same antibodies are also present in individuals once the SARS-CoV-2 infection is resolved, at levels that depend on the duration and severity of clinical symptoms.[SUP]4[/SUP] The efficacy of passive antibody therapy has been associated with the concentration of nAbs in the convalescent plasma (CP) of recovered patients.[SUP]5,6[/SUP] Thus, it would be useful to immediately identify donors with high nAbs titers. The gold-standard test used to detect nAbs is the plaque reduction neutralization test (PRNT).
Keywords: Covid-19; PRNT; RBD; SARS-CoV-2; immunoassay; neutralizing antibodies.
. 2021 Apr 18;e13573.
doi: 10.1111/eci.13573. Online ahead of print.
SARS-CoV-2 antibodies: comparison of three high-throughput immunoassays versus the neutralization test
Riccardo Laterza[SUP] 1 [/SUP], Annalisa Schirinzi[SUP] 1 [/SUP], Rossella Bruno[SUP] 2 [/SUP], Rosa Genco[SUP] 1 [/SUP], Renato Contino[SUP] 1 [/SUP], Angelo Ostuni[SUP] 2 [/SUP], Francesca Di Serio[SUP] 1 [/SUP]
Affiliations
- PMID: 33870493
- DOI: 10.1111/eci.13573
Abstract
On March 11, 2020 the World Health Organization (WHO) declared the novel coronavirus (SARS-CoV-2) outbreak a global pandemic.[SUP]1[/SUP] Currently, no specific therapy has proved to be effective against the infection. With the approval by WHO[SUP]2[/SUP] of the first vaccine for emergency use against SARS-CoV-2 on December 31, 2020, it is important to understand the strength and duration of immunity after administration, which is induced by neutralizing anti-SARS-CoV-2 S antibodies (nAbs).[SUP]3[/SUP] The same antibodies are also present in individuals once the SARS-CoV-2 infection is resolved, at levels that depend on the duration and severity of clinical symptoms.[SUP]4[/SUP] The efficacy of passive antibody therapy has been associated with the concentration of nAbs in the convalescent plasma (CP) of recovered patients.[SUP]5,6[/SUP] Thus, it would be useful to immediately identify donors with high nAbs titers. The gold-standard test used to detect nAbs is the plaque reduction neutralization test (PRNT).
Keywords: Covid-19; PRNT; RBD; SARS-CoV-2; immunoassay; neutralizing antibodies.